• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Throat Cancer - Pipeline Review, H1 2012 Product Image

Throat Cancer - Pipeline Review, H1 2012

  • Published: April 2012
  • 214 pages
  • Global Markets Direct

Throat Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Throat Cancer - Pipeline Review, H1 2012', provides an overview of the Throat Cancer therapeutic pipeline. This report provides information on the therapeutic development for Throat Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Throat Cancer. 'Throat Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Throat Cancer.
- A review of the Throat Cancer products under development by companies and universities/research institutes based on information derived READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Throat Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Throat Cancer
Throat Cancer Therapeutics under Development by Companies
Throat Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Throat Cancer Therapeutics – Products under Development by Companies
Throat Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Throat Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
YM BioSciences Inc.
Cyclacel Pharmaceuticals Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Biotech Pharmaceuticals Co., Ltd.
Throat Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Seliciclib - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
HPPH - Drug Profile
Vorinostat + Capecitabine - Drug Profile
Cetuximab + Cisplatin + Radiotherapy - Drug Profile
Cisplatinum + Radiotherapy - Drug Profile
Xeloda + Oxaliplatin - Drug Profile
5-Fluorouracil + Hydroxyurea + Bevacizumab + Radiation Therapy - Drug Profile
Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy1 - Drug Profile
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Cisplatin + Xeloda + Radiation Therapy - Drug Profile
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
GW786034 - Drug Profile
Gemcitabine + Cisplatinn - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Cetuximab + Radiation Therapy - Drug Profile
Carboplatin + Paclitaxel - Drug Profile
Fludarabine + Radiation Therapy - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Radiation Therapy + Cetuximab - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin - Drug Profile
Bevacizumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
Radiotherapy + Cisplatin + Fluorouracil - Drug Profile
Docetaxel + Cisplatin + Fluorouracil - Drug Profile
Celecoxib - Drug Profile
Cisplatin + Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
TheraCIM - Drug Profile
Vorinostat + Cisplatin + Radiation Therapy - Drug Profile
Gemcitabine + Carboplatin - Drug Profile
Velcade - Drug Profile
Carboplatin + Cisplatin + Docetaxel + Fluorouracil + Lapatinib + Radiation Therapy - Drug Profile
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Foscan - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiotherapy - Drug Profile
TS-1 + Nedaplatin + Radiation Therapy - Drug Profile
Cisplatin + 5-Fluorouracil + Celecoxib + Radiation Therapy - Drug Profile
S-1 + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Docetaxel + Radiation Therapy - Drug Profile
S-1 + Radiation Therapy - Drug Profile
Minocycline - Drug Profile
Docetaxel + 5-Fluorouracil + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
Mitomycin C + Epirubicin + Cisplatin + 5-Fluorouracil + Leucovorin - Drug Profile
Docetaxel + Radiation Therapy - Drug Profile
Carbogen + Nicotinamide + Radiotherapy - Drug Profile
Cisplatin + Intensity-Modulated Radiation Therapy - Drug Profile
Cisplatin + Fluorouracil + Docetaxel + Cetuximab - Drug Profile
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile
Cisplatinum + Fluorouracil + Radiotherapy - Drug Profile
Recombinant Epstein-Barr Virus (EBV) Vaccine - Drug Profile
Cisplatin + Cetuximab + 5-Fluorouracil + Taxotere + Radiation Therapy - Drug Profile
5-Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile
Interleukin + NK Cells - Drug Profile
Cetuximab + Docetaxel + Cisplatin + 5-FU - Drug Profile
Paclitaxel + Carboplatin + Cisplatin + Amifostine Trihydrate + Radiation Therapy - Drug Profile
Panitumumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Bevacizumab + Cisplatin + Fluorouracil - Drug Profile
Cetuximab + Cisplatin + Docetaxel + 5-FU - Drug Profile
Cetuximab + Cisplatin + Radiation Therapyy - Drug Profile
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Adriamycin + Lomustine - Drug Profile
Erbitux + Docetaxel + Cisplatin - Drug Profile
Amifostine + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Lapatinib Ditosylate + Capecitabine - Drug Profile
Taxotere + Cisplatin + 5-FU - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Erbitux + Radiation Therapy - Drug Profile
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Erbitux + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + Fluorouracil + Carboplatin + Cetuximab + Radiation Therapy - Drug Profile
Nedaplatin + Radiation Therapy - Drug Profile
Modified Vaccinia Ankara Vaccine - Drug Profile
Axitinib - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
Sunitinib + Cisplatin + Gemcitabine - Drug Profile
Docetaxel + Cisplatin + Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
VTX-2337 + Cetuximab - Drug Profile
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
LBH589 + RAD001 - Drug Profile
S-1 + Radiation Therapy - Drug Profile
MK2206 - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Famitinib - Drug Profile
SOX - Drug Profile
MK-2206 - Drug Profile
Docetaxel + Cisplatin + Radiation Therapy - Drug Profile
Famitinib + Cisplatin + Radiation Therapy - Drug Profile
Throat Cancer Therapeutics – Drug Profile Updates
Throat Cancer Therapeutics – Discontinued Products
Throat Cancer Therapeutics - Dormant Products
Throat Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Throat Cancer, H1 2012
Products under Development for Throat Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
F. Hoffmann-La Roche Ltd., H1 2012
YM BioSciences Inc., H1 2012
Cyclacel Pharmaceuticals Inc., H1 2012
Jiangsu Hengrui Medicine Co., Ltd., H1 2012
Biotech Pharmaceuticals Co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Throat Cancer Therapeutics – Drug Profile Updates
Throat Cancer Therapeutics – Discontinued Products
Throat Cancer Therapeutics – Dormant Products
Throat Cancer Therapeutics – Dormant Products (Contd..1)
Throat Cancer Therapeutics – Dormant Products (Contd..2)
Throat Cancer Therapeutics – Dormant Products (Contd..3)

List of Figures
Number of Products under Development for Throat Cancer, H1 2012
Products under Development for Throat Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos